SEC Form 4 · accession 0001140361-17-022601
KalVista Pharmaceuticals, Inc. · KALV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edward P. Feener
Officer — Chief Scientific Officer
Period of report
May 25, 2017
Accepted (ET)
May 26, 2017 · 6:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348911
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $7.07 | May 25, 2017 | A | 33,800 | A | — | May 24, 2027 | Common Stock | 33,800 | 33,800 | D |
Explanation of responses
- F1The option vests over a 4 year period: 1/48th on June 25, 2017 after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date.